Last reviewed · How we verify
CM336_group 4a
CM336_group 4a is a Small molecule drug developed by Keymed Biosciences Co.Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | CM336_group 4a |
|---|---|
| Sponsor | Keymed Biosciences Co.Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CM336_group 4a CI brief — competitive landscape report
- CM336_group 4a updates RSS · CI watch RSS
- Keymed Biosciences Co.Ltd portfolio CI
Frequently asked questions about CM336_group 4a
What is CM336_group 4a?
CM336_group 4a is a Small molecule drug developed by Keymed Biosciences Co.Ltd.
Who makes CM336_group 4a?
CM336_group 4a is developed by Keymed Biosciences Co.Ltd (see full Keymed Biosciences Co.Ltd pipeline at /company/keymed-biosciences-co-ltd).
What development phase is CM336_group 4a in?
CM336_group 4a is in Phase 1.
Related
- Manufacturer: Keymed Biosciences Co.Ltd — full pipeline
- Compare: CM336_group 4a vs similar drugs
- Pricing: CM336_group 4a cost, discount & access